Johnson & Johnson on August 21, 2025, went on to announce that it will be adding another 160,000 ft.² dedicated manufacturing facility in its Fujifilm site based at Holly Springs, NC. This is going to be a part of a $2 billion expansion by J&J in the next 10 years in order to expand the company’s manufacturing capacity across the United States of America. The facility is going to focus on the manufacturing of advanced medicines, and the company has already stated that it also plans to add more advanced manufacturing facilities throughout the US and also eyes expanding the present facilities.
According to the chairman and chief executive officer of Johnson & Johnson, Joaquin Duato, J&J has more manufacturing facilities in the US than in any other country, and they would like to continue to strengthen their presence in it. Due to the recent signing of the one big beautiful bill act, they are going to continue to expand their investment throughout the US so as to lead the next era when it comes to healthcare innovation.
This is a part of larger US expansion
It is well to be noted that in March 2025, J&J went on to announce an investment of $55 billion in US manufacturing, technology, and research & development in the next four years, which includes –
– Construction of a facility in Wilson, NC, which will employ over 500 people when it becomes fully operational and also create almost 5000 construction jobs at the development of the site.
– Research and development structure in order to come up with life-saving as well as life-changing treatments in areas like neuroscience, immunology, oncology, and cardiovascular disease, as well as robotic surgery.
Apparently, these announcements would accelerate almost 140 years of legacy when it comes to the American innovation engine going ahead and tackling the toughest healthcare challenges of the world, said Duato in a press release. The increased investment in the US starts with the groundbreaking of a North Carolina high-tech facility, which will not just add to US jobs but also manufacture certain cutting-edge medicines so as to treat patients throughout America and even the world.
White House actions
In the early part of August 2025, J&J happened to be one of the companies on the receiving end of letters that were sent by the Trump administration that insisted prescription drug prices be lowered across the US. In what has been termed the most favored nation price strategy, the White House has been in touch with pharmaceutical companies on ways drug pricing can actually get decreased.
Apparently, the ongoing tariff situation also made certain major impacts within the pharmaceutical sector. Interestingly, a survey went on to find that the tariff-driven expenditures are growing and supply is strained, with people reporting that the tariffs are going to significantly affect their operations or even, for that matter, the supply chain.
Other companies eyeing the US in terms of investment
Apart from $2 billion expansion by J&J, other pharmaceutical companies are also making investments within the US facilities. On August 13, 2025, AbbVie went out to announce that it was expanding the US API production with an almost $195 million investment in the North Chicago Manufacturing plant, thereby allowing the company to deepen the chemical synthesis capacities across the US.
Interestingly, Bora Pharmaceuticals also went on to announce an investment in August 2025. The company is going to be expanding its manufacturing and packaging capacities in the Maple Grove, Minnesota facility. In July 2025, AstraZeneca announced a $50 billion investment within the manufacturing as well as research and development facilities across the US by the end of the decade. In June 2025, Hikma Pharmaceuticals announced that it was investing $1 billion in expanding the generic drug research and development and also manufacturing across Ohio as well as New Jersey.
